Back to News Items

August 2012 : New Article - Life Extending Lenalidomide is a Viable Treatment Option

Main bullet points:

  • Patients with myelodysplastic syndrome and multiple myeloma find treatment with Lenalidomide to be life extending.
  • The patent for Lenalidomide, known as Revlimid, expires on October 4, 2019.
  • Sales of Revlimid (Lenalidomide) totaled $3.2 billion in 2011.
  • Maintenance therapy with Lenalidomide significantly delayed the progression of multiple myeloma for participants in three documented studies.
  • Patients in one particular trial group lived 26 months longer after receiving Lenalidomide as maintenance therapy. 



Dun and Bradstreet